BiotechTube

RotaTeq® + NeisVac-C®

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Meningitis, Meningococcal

Conditions

Meningitis, Meningococcal, Rotavirus Infections

Trial Timeline

Feb 13, 2007 → Oct 23, 2007

NCT ID
NCT00443846

About RotaTeq® + NeisVac-C®

RotaTeq® + NeisVac-C® is a phase 3 stage product being developed by Merck for Meningitis, Meningococcal. The current trial status is completed. This product is registered under clinical trial identifier NCT00443846. Target conditions include Meningitis, Meningococcal, Rotavirus Infections.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00443846Phase 3Completed

Competing Products

20 competing products in Meningitis, Meningococcal

See all competitors
ProductCompanyStageHype Score
DaptomycinMerckPre-clinical
23
Meningococcal ACWY conjugate vaccineNovartisPhase 3
77
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus VaccineNovartisApproved
85
Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaPNovartisPhase 3
77
Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and MenveoNovartisPhase 3
77
Meningococcal ACWY conjugate vaccineNovartisPhase 3
77
MenACWY-CRM + MenC-CRM + DTaP-Hib-IPV + PC7 + MMR + VaricellaNovartisPhase 2
52
Hib-CRM197 + Hib-TTNovartisPhase 3
77
Novartis Meningococcal ACWY Conjugate Vaccine + Tdap Vaccine + Novartis Meningococcal ACWY Conjugate VaccineNovartisPhase 3
77
MenACWY-CRM conjugate vaccine, adjuvanted + MenACWY polysaccharide vaccine + MenACWY-CRM conjugate vaccine, unadjuvantedNovartisPhase 2
52
meningococcal B vaccine & meningococcal ACYW conjugate vaccineNovartisPhase 2
52
Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosineNovartisPhase 2
52
4CMenBNovartisApproved
85
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccineNovartisPhase 3
77
Meningococcal (group B) multicomponent recombinant adsorbed vaccineNovartisPhase 3
77
MenACWY-CRM197 (two doses) + MenC + PCV7 + DTPa-IPV-HepB-Hib + MenACWY-CRM197 (one dose)NovartisPhase 3
77
MenACWY-CRM197 + DTaP (Diptheria, Tetanus, Pertussis) Vaccine + Hib (Haemophilus influenza b) Vaccine + IPV (Inactivated Polio Vaccine) Vaccine + Pneumococcal conjugate Vaccine + MMR (Measles, Mumps, and Rubella) Vaccine + Varicella Vaccine + Hepatitis A VirusNovartisPhase 3
77
Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years)NovartisPhase 3
77
Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Control + Meningococcal B vaccine with antipyreticNovartisPhase 2
52
Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1) + Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2) + Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3) + Infanrix Hexa + Menjugate + PrevenarNovartisPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85